Novozymes Biopharma secures CPhI 2009 innovation award for its albufuse technology
Advertisement
Novozymes Biopharma, part of Novozymes A/S, has claimed the Bronze Innovation Award at the CPhI Worldwide 2009 in Madrid, Spain, for its albumin fusion technology, albufuse. The CPhI Innovation Awards are designed to reward organizations that play a leading role in delivering groundbreaking innovations within the pharmaceutical industry and the company is delighted to add this accolade to its ever-growing collection of industry awards.
Novozymes Biopharma's albufuse technology provides molecular fusion of albumin to protein drug candidates for improved half-life and bioavailability. The simple, single step expression platform is a natural alternative to other technologies such as PEGylation, a chemical conjugation, offering less frequent administration and reduced dosage. In addition, the technology offers customers the benefits of absolutely consistent products, with more simple production and competitive costs enabling long-term supply in large volume quantities.
The CPhI Innovation Awards are established as the showcase for outstanding work in developing research and technology, setting the standards for the pharmaceutical manufacturing industry. The award's judging panel took into consideration a number of factors including effective development of the technology and the key benefits it offers to the pharmaceutical industry.
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Antisense Pharma Granted Patents on Medical Device for Application of Neurotherapeutics
Molecular Profiles Invests £9 million in New Facility To Increase Manufacturing Capabilities for Phase I and II Clinical Trials
EyeTechCare raises EUR 7.5 million in a second funding round and speeds up its development
David Evans steps down as chairman of the board for Horizon Discovery
New clinical and preclinical data on Basilea's novel antibiotic BAL30072 against multidrug-resistant Gram-negative superbugs
Parkinson’s researchers test a new approach against motor disorders
New virus drug will have to shoot at moving targets
New research may lead to improved diagnosis of autism
BioGaia initiates investigative study in type 2 diabetics
Viruses flourish in guts of healthy babies
Amorfix Life Sciences and Biogen Idec to collaborate on research for ALS disease